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Abstract Proton pump inhibitor (PPI)-induced hypomag-
nesemia is currently a major topic. Patients undergoing
Roux-en-Y gastric bypass are generally prescribed PPI
prophylaxis after surgery. We investigated the prevalence
of hypomagnesemia in our bariatric population. We
reviewed the files of 1000 postoperative patients for serum
magnesium level during PPI use. We found only five cases
of hypomagnesemia, none of which was evidently related
to PPI use. We conclude that the risk of hypomagnesemia
during 1 year of prophylactic PPI use after Roux-en-Y
gastric bypass (RYGB) is minimal and laboratory screen-
ing is probably not necessary.
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Introduction
Hypomagnesemia following proton pump inhibitor (PPI) use
was first reported in 2006 [1]. Several hundred cases have
now been described [2]. A recent systematic review confirmed
that PPI use significantly increases the risk of hypomagnese-
mia [3]. The relationship between the duration of PPI use
and development of hypomagnesemia is unknown, but it is
advised to monitor magnesium levels after more than
3 months of PPI use [4]. Other known risk factors for
hypomagnesemia are diabetes mellitus, renal disease, age
>65, and use of diuretics [3, 5]. Hypomagnesemia can lead
to vomiting, diarrhea, tetany, seizures, QT-interval prolon-
gation, and other electrolyte disturbances [2]. In most bar-
iatric centers, patients are prescribed PPI prophylaxis after
surgery. In our center, a PPI (pantoprazole 40 mg once
daily) is prescribed to all patients for 1 year following
surgery. After the first year, the PPI is continued only in
specific cases, such as patients who suffered from a mar-
ginal ulcer. We investigated the prevalence of hypomagne-
semia in our patient population.
Methods
We reviewed the files of 1000 consecutive patients who
underwent laparoscopic Roux-en-Y gastric bypass (RYGB)
in our high-volume bariatric center between December 2012
and February 2014. Prior to surgery, patients underwent a
screening program with laboratory testing, including serum
magnesium levels. These same tests were routinely performed
at 6 and 12 months after surgery. Patients receive lifelong
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supplementation with a daily multivitamin tablet, containing
125 mg magnesium.
Data were collected from the patient records. For this type
of study, formal consent was not required. Serum magnesium
level for all postoperative measurements was determined with
the Architect ci8200 (Abbott diagnostics, IL, USA).
Hypomagnesemia was defined as a magnesium level below
the locally established lower reference value of 0.65 millimole
per liter (mmol/L). In some of the cases, the preoperative
magnesium level was determined with a different analyzer
(Beckman Coulter LX-20 chemistry analyzer). This does not
influence the results of this study as this concerns only preop-
erative measurements and the reference values are similar.
However, a comparison of pre- and postoperative means could
not be done.
Results
Out of 1000 files studied, 931 patients had a magnesium level
determined at either 6 or 12 months (214 patients) after sur-
gery, or at both time points (717 patients). For 69 patients,
there was no magnesium level available at both 6 and
12 months. Mean and standard deviation for each time point
are shown in Table 1. Five patients had hypomagnesemia at
6 months, all suffered from diabetes (Table 2). Four of
these patients already had hypomagnesemia preoperative-
ly, two of them used a PPI preoperatively. Two patients had
a normalized magnesium at 12 months without additional
treatment despite continuing PPI use. One patient had a
normal magnesium (0.67 mmol/L) preoperatively, despite
already using a PPI at that time. This patient was 62 years
old and suffered from diabetes mellitus type 2. The mag-
nesium had decreased at 6 months (0.62 mmol/L) and
12 months (0.61 mmol/L). She was advised to discontinue
PPI use.
Conclusion
In this retrospective study of 931 patients on prophylactic
PPI after RYGB, we found no case of hypomagnesemia
that was evidently related to the PPI use. This might be
explained by the absence of other risk factors. Bariatric
patients are relatively young, experience significant im-
provement in diabetes mellitus after surgery, and often
discontinue the use of diuretics because of normalized
blood pressure. Furthermore, the mean serum magnesium
level is known to increase after RYGB, possibly due to
improved insulin sensitivity or increased parathyroid hor-
mone levels [6, 7].
We conclude that the risk of hypomagnesemia during
1 year of prophylactic PPI use after RYGB is minimal
and laboratory screening is probably not necessary.
Table 2 All patients with postoperative hypomagnesemia
Gender Age (years) Diabetes Preoperative PPI use Renal disease Preoperative (mmol/L) 6 months (mmol/L) 12 months (mmol/L)
Male 44 Yes No Yes 0.56 0.55 0.61
Male 59 Yes No No 0.62 0.57 Unknown
Female 53 Yes Yes Yes 0.58 0.59 0.80
Female 53 Yes No No 0.58 0.62 0.69
Female 61 Yes Yes No 0.67 0.62 0.61
Lower reference value = 0.65 millimole per liter (mmol/L); renal disease = eGFR<60
PPI proton pump inhibitor, eGFR estimated glomerular filtration rate









Minimum and maximum levels
(mmol/L)
Number of patients below
reference value
Preoperative 983 0.825 0.070 0.56–1.08 11
6 months 862 0.839 0.064 0.55–1.05 5
12 months 783 0.848 0.066 0.61–1.09 2
mmol/L millimole per liter
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